We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current MEDCL market cap is 356.99M. The company's latest EPS is EUR -1.1011 and P/E is -11.15.
| Year End 31 March 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 4.08M | 6M | 11.83M | 8.55M | 14.38M |
| Operating Income | -15.52M | -19.33M | -15.37M | -23.7M | -24.05M |
| Net Income | -19.69M | -23.92M | -19.02M | -24.81M | -32.01M |
| Year End 31 March 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 37.98M | 27.31M | 63.61M | 44.3M | 29.34M |
| Total Liabilities | 31.74M | 43.27M | 54.69M | 57.67M | 71.63M |
| Total Equity | 6.24M | -15.96M | 8.92M | -13.37M | -42.29M |
| Year End 31 March 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -15.93M | -12.54M | -12.14M | -21.36M | -21.01M |
| Investing | -832k | 72k | -1.06M | -316k | 1.3M |
| Financing | 29.24M | 3.56M | 47.92M | -800k | 1.56M |
| Market Cap | 356.99M |
| Price to Earnings Ratio | -11.15 |
| Price to Sales Ratio | 24.82 |
| Price to Cash Ratio | 55.19 |
| Price to Book Ratio | -8.44 |
| Dividend Yield | - |
| Shares Outstanding | 29.07M |
| Average Volume (1 week) | 306.73k |
| Average Volume (1 Month) | 112.98k |
| 52 Week Change | 37.98% |
| 52 Week High | 12.48 |
| 52 Week Low | 5.25 |
| Spread (Intraday) | 0.14 (1.13%) |
| Company Name | Medincell SA |
| Address |
3 rue des freres lumiere jacou, occitan 34830 |
| Website | https://www.medincell.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
